Etanercept
| Evidence Level: L3 | Predicted Indications: 6 |
Table of Contents
Etanercept: From Rheumatoid Arthritis to Rheumatoid Vasculitis
One-Sentence Summary
Etanercept is a TNF-alpha blocker sold as Enbrel in the US. The literature in the Evidence Pack describes it as approved for rheumatoid arthritis and other inflammatory arthritides. The TxGNN model predicts it may be effective for rheumatoid vasculitis, but the direct support is weak. Only 1 relevant clinical trial (in a different vasculitis, and without a positive result) and 1 systematic review exist, while multiple reports link etanercept to causing vasculitis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the license data (literature describes rheumatoid arthritis and other inflammatory arthritides) |
| Predicted New Indication | Rheumatoid vasculitis |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L3 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 5 records (all under BLA103795) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the Evidence Pack. Etanercept is a TNF-alpha antagonist (a soluble TNF receptor-Fc fusion protein), and its efficacy in rheumatoid arthritis is well established.
Rheumatoid vasculitis is a severe extra-articular manifestation of rheumatoid arthritis. TNF-alpha drives endothelial inflammation, so blocking it is mechanistically plausible. A 2021 systematic review evaluated biological drugs in rheumatoid vasculitis.
Two findings weaken this reasoning:
- The only controlled etanercept trial in any vasculitis (Wegener’s granulomatosis, Phase 2) did not show benefit.
- Many case reports and cohort studies describe paradoxical vasculitis during etanercept treatment, so the safety signal runs opposite to the predicted benefit.
Clinical Trial Evidence
No trial tests etanercept directly in rheumatoid vasculitis.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00001901 | Phase 2 | Completed | 60 | Etanercept in Wegener’s granulomatosis, a different vasculitis. Informs TNF blockade in vasculitis but is not direct evidence for rheumatoid vasculitis. |
| NCT07138898 | Phase 2 | Not yet recruiting | 80 | Peri-operative immunosuppressant management in rheumatology patients having shoulder arthroplasty. Does not test etanercept for vasculitis. |
| NCT01557322 | N/A | Completed | 1754 | Real-world treatment pathways in moderate RA, etanercept vs non-biologic therapy. No vasculitis endpoint. |
| NCT05696106 | N/A | Unknown | 750000 | Registry of new immune-mediated inflammatory disease under biologics. Safety and epidemiology study, not efficacy. |
| NCT02590562 | N/A | Completed | 808 | Cross-sectional study of biologic DMARD use in RA in China. Not relevant to vasculitis efficacy. |
| NCT01579006 | N/A | Completed | 184 | Non-interventional tocilizumab study in RA. Different drug and not relevant to vasculitis. |
Literature Evidence
No RCTs were found. The retrieved literature is a systematic review, reviews, cohort data and case reports, and most items describe etanercept-associated vasculitis rather than treatment benefit.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33058033 | 2021 | Systematic review | Clin Rheumatol | PRISMA-based review of biological drugs in rheumatoid vasculitis. The retrieved abstract does not include results. |
| 28391344 | 2017 | Review | Nephrol Dial Transplant | Discusses whether TNF-alpha blockade has a role in ANCA-associated vasculitis, given TNF-alpha’s role in its pathophysiology. |
| 28123776 | 2017 | Cohort | RMD Open | BSRBR-RA data comparing lupus-like and vasculitis-like events in TNF-inhibitor-treated RA patients vs non-biologic DMARD-treated patients. |
| 15468348 | 2004 | Review | J Rheumatol | Reviews TNF-alpha blockade and the risk of vasculitis. |
| 15853915 | 2005 | Case series | Scand J Immunol | Immunology of cutaneous vasculitis associated with both etanercept and infliximab. |
| 12209493 | 2002 | Case report | Arthritis Rheum | Accelerated nodulosis and vasculitis after etanercept for RA. |
| 11792895 | 2002 | Case report | Rheumatology (Oxford) | Cutaneous vasculitis associated with etanercept and infliximab. |
| 15801034 | 2005 | Case report | J Rheumatol | Proliferative lupus nephritis and leukocytoclastic vasculitis during etanercept treatment. |
| 25544845 | 2014 | Case report | Case Rep Med | Large vessel vasculitis in an RA patient on anti-TNF therapy. |
| 31632872 | 2019 | Case report | Cureus | Etanercept-associated nephropathy, with autoantibody formation under anti-TNF therapy. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA103795 | ENBREL (Immunex Corporation) | Solution | Not recorded in the license data |
The 5 license records are identical entries under the same BLA.
Safety Considerations
- Literature signal: Multiple case reports and cohort analyses describe cutaneous vasculitis, large-vessel vasculitis, lupus-like events and nephropathy during etanercept therapy. This is directly relevant to any vasculitis indication.
Please refer to the package insert for formal warnings, contraindications and drug interactions, since none are available in the Evidence Pack.
Conclusion and Next Steps
Decision: Hold
Rationale: Support is limited to a plausible TNF mechanism and one systematic review. The only controlled etanercept trial in vasculitis (Wegener’s granulomatosis) showed no benefit, and etanercept has repeatedly been associated with paradoxical vasculitis. The 99.71% model score is not backed by direct clinical evidence.
To proceed, the following is needed:
- The results of the 2021 systematic review (PMID 33058033) on biologics in rheumatoid vasculitis, to see whether any etanercept-treated patients improved
- The outcome of NCT00001901 (Wegener’s granulomatosis) in detail
- Package insert warnings and contraindications from the FDA label, which currently block safety screening
- Detailed mechanism of action data from DrugBank
- A benefit-risk analysis weighing etanercept-associated vasculitis against any potential benefit
This report is for research reference only and does not constitute medical advice. Predicted indications require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.